K192017: Citrasate Liquid Acid Concentrate, NaturaLyte Liquid Acid Concentrate (FDA 510(k) & Recall Dossier)

U.S. FDA 510(k) Premarket Notification K192017 (Citrasate Liquid Acid Concentrate, NaturaLyte Liquid Acid Concentrate, cleared 2020-04-24 for Fresenius Medical Care Renal Therapies Group, LLC) reconciled with CDRH recall records on Predicate Ledger.

Reconciled U.S. FDA 510(k) Premarket Notification Metadata for K192017
Regulatory FieldVerified FDA Record
FDA 510(k) NumberK192017
Cleared Device Trade / Generic NameCitrasate Liquid Acid Concentrate, NaturaLyte Liquid Acid Concentrate
FDA Applicant on FilingFresenius Medical Care Renal Therapies Group, LLC
FDA 3-Letter Product ClassificationProduct Code KPO
FDA Substantial Equivalence Decision Date2020-04-24
De-Broadcasted Recall LinkageLinked to at least one historical or open CDRH/openFDA recall notice (1976 to 2026)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.

Inspect consolidated manufacturer lineage at Fresenius Medical Care Renal Therapies Group, LLC, compare peer devices under FDA Product Code KPO, or browse all 20 FDA clinical specialties.

Meru AI Healthcare Data Engineering: Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI → · AI for Healthcare Practice · Healthcare Price & Patent-Cliff Crosswalk Guide.